Financial Results Announcement - GRI Bio, Inc. announced its financial results for the year ended December 31, 2024, on March 17, 2025[5]. - A press release detailing the financial results was issued as Exhibit 99.1[7]. - The report does not include specific financial metrics or performance indicators in the provided content[6]. - No specific user data, future outlook, or guidance was provided in the available content[6]. Company Classification and Trading - The company is classified as an emerging growth company under the Securities Act of 1933[4]. - The common stock of GRI Bio, Inc. is traded on The Nasdaq Capital Market under the symbol GRI[3]. - The report indicates that the information is not deemed "filed" for purposes of the Securities Exchange Act of 1934[6]. Company Information - The company is headquartered in La Jolla, CA, with a principal executive office address at 2223 Avenida de la Playa, Suite 208[3]. - The Chief Financial Officer, Leanne Kelly, signed the report on behalf of GRI Bio, Inc.[10]. Product and Market Activity - There are no mentions of new products, technologies, market expansion, or acquisitions in the provided documents[6].
GRI Bio(GRI) - 2024 Q4 - Annual Results